These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 37525333)

  • 1. Integrated analysis of the transcriptome and its interaction with the metabolome in metabolic associated fatty liver disease: Gut microbiome signatures, correlation networks, and effect of PNPLA3 genotype.
    Mascardi MF; Mazzini FN; Suárez B; Ruda VM; Marciano S; Casciato P; Narvaez A; Haddad L; Anders M; Orozco F; Tamaroff AJ; Cook F; Gounarides J; Gutt S; Gadano A; García CM; Marro ML; Penas Steinhardt A; Trinks J
    Proteomics; 2023 Sep; 23(18):e2200414. PubMed ID: 37525333
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma and stool metabolomics to identify microbiota derived-biomarkers of metabolic dysfunction-associated fatty liver disease: effect of PNPLA3 genotype.
    Mazzini FN; Cook F; Gounarides J; Marciano S; Haddad L; Tamaroff AJ; Casciato P; Narvaez A; Mascardi MF; Anders M; Orozco F; Quiróz N; Risk M; Gutt S; Gadano A; Méndez García C; Marro ML; Penas-Steinhardt A; Trinks J
    Metabolomics; 2021 Jun; 17(7):58. PubMed ID: 34137937
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of Gut Microbiome in Korean Patients with Metabolic Associated Fatty Liver Disease.
    Oh JH; Lee JH; Cho MS; Kim H; Chun J; Lee JH; Yoon Y; Kang W
    Nutrients; 2021 Mar; 13(3):. PubMed ID: 33801023
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mining Gut Microbiota From Bariatric Surgery for MAFLD.
    Wu WK; Chen YH; Lee PC; Yang PJ; Chang CC; Liu KL; Hsu CC; Huang CC; Chuang HL; Sheen LY; Liu CJ; Wu MS
    Front Endocrinol (Lausanne); 2021; 12():612946. PubMed ID: 33897617
    [TBL] [Abstract][Full Text] [Related]  

  • 5. African genetic ancestry is associated with lower frequency of PNPLA3 G allele in non-alcoholic fatty liver in an admixed population.
    Cavalcante LN; Porto J; Mazo D; Longatto-Filho A; Stefano JT; Lyra AC; Carrilho FJ; Reis RM; Alves VAF; Sanyal AJ; Oliveira CP
    Ann Hepatol; 2022; 27(6):100728. PubMed ID: 35710086
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mapping the human oral and gut fungal microbiota in patients with metabolic dysfunction-associated fatty liver disease.
    Niu C; Tu Y; Jin Q; Chen Z; Yuan K; Wang M; Zhang P; Luo J; Li H; Yang Y; Liu X; Mao M; Dong T; Tan W; Hu X; Pan Y; Hou L; Ma R; Huang Z
    Front Cell Infect Microbiol; 2023; 13():1157368. PubMed ID: 37180439
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Network of Interactions Between Gut Microbiome, Host Biomarkers, and Urine Metabolome in Carotid Atherosclerosis.
    Li RJ; Jie ZY; Feng Q; Fang RL; Li F; Gao Y; Xia HH; Zhong HZ; Tong B; Madsen L; Zhang JH; Liu CL; Xu ZG; Wang J; Yang HM; Xu X; Hou Y; Brix S; Kristiansen K; Yu XL; Jia HJ; He KL
    Front Cell Infect Microbiol; 2021; 11():708088. PubMed ID: 34692558
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Understanding the Role of the Gut Microbiome and Microbial Metabolites in Non-Alcoholic Fatty Liver Disease: Current Evidence and Perspectives.
    Vallianou N; Christodoulatos GS; Karampela I; Tsilingiris D; Magkos F; Stratigou T; Kounatidis D; Dalamaga M
    Biomolecules; 2021 Dec; 12(1):. PubMed ID: 35053205
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The microbial metabolome in metabolic-associated fatty liver disease.
    Li M; Rajani C; Zheng X; Jia W
    J Gastroenterol Hepatol; 2022 Jan; 37(1):15-23. PubMed ID: 34850445
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ecological shifts of salivary microbiota associated with metabolic-associated fatty liver disease.
    Wang M; Yan LY; Qiao CY; Zheng CC; Niu CG; Huang ZW; Pan YH
    Front Cell Infect Microbiol; 2023; 13():1131255. PubMed ID: 36864882
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A universal plasma metabolites-derived signature predicts cardiovascular disease risk in MAFLD.
    Li Z; Gong R; Chu H; Zeng J; Chen C; Xu S; Hu L; Gao W; Zhang L; Yuan H; Cheng Z; Wang C; Du M; Zhu Q; Zhang L; Rong L; Hu X; Yang L
    Atherosclerosis; 2024 May; 392():117526. PubMed ID: 38581738
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of microbiome and metabolite analyses in patients with metabolic associated fatty liver disease and type II diabetes mellitus.
    Yang Q; Zhang L; Li Q; Gu M; Qu Q; Yang X; Yi Q; Gu K; Kuang L; Hao M; Xu J; Yang H
    BMC Microbiol; 2022 Apr; 22(1):105. PubMed ID: 35421921
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of Gut Microbiota and its Metabolites on Progression of Metabolic Associated Fatty Liver Disease.
    Wang YY; Lin HL; Wang KL; Que GX; Cao T; Zhu LM; Yang X; Yang XF
    Chin Med Sci J; 2023 Dec; 38(4):286-296. PubMed ID: 38097345
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characteristics of gut microbiota in patients with metabolic associated fatty liver disease.
    Yang C; Xu J; Xu X; Xu W; Tong B; Wang S; Ji R; Tan Y; Zhu Y
    Sci Rep; 2023 Jun; 13(1):9988. PubMed ID: 37340081
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined analysis of gut microbiota, diet and PNPLA3 polymorphism in biopsy-proven non-alcoholic fatty liver disease.
    Lang S; Martin A; Zhang X; Farowski F; Wisplinghoff H; J G T Vehreschild M; Krawczyk M; Nowag A; Kretzschmar A; Scholz C; Kasper P; Roderburg C; Mohr R; Lammert F; Tacke F; Schnabl B; Goeser T; Steffen HM; Demir M
    Liver Int; 2021 Jul; 41(7):1576-1591. PubMed ID: 33896117
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Frequency of the PNPLA3 rs738409 polymorphism and other genetic loci for liver disease in a Guatemalan adult population.
    Lazo M; Xie J; Alvarez CS; Parisi D; Yang S; Rivera-Andrade A; Kroker-Lobos MF; Groopman JD; Guallar E; Ramirez-Zea M; Arking DE; McGlynn KA
    Liver Int; 2022 Jun; 42(6):1470-1474. PubMed ID: 35365950
    [No Abstract]   [Full Text] [Related]  

  • 17. Beneficial effects of exercise on gut microbiota functionality and barrier integrity, and gut-liver crosstalk in an
    Carbajo-Pescador S; Porras D; García-Mediavilla MV; Martínez-Flórez S; Juarez-Fernández M; Cuevas MJ; Mauriz JL; González-Gallego J; Nistal E; Sánchez-Campos S
    Dis Model Mech; 2019 Apr; 12(5):. PubMed ID: 30971408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Microbiome signatures of progression toward celiac disease onset in at-risk children in a longitudinal prospective cohort study.
    Leonard MM; Valitutti F; Karathia H; Pujolassos M; Kenyon V; Fanelli B; Troisi J; Subramanian P; Camhi S; Colucci A; Serena G; Cucchiara S; Trovato CM; Malamisura B; Francavilla R; Elli L; Hasan NA; Zomorrodi AR; Colwell R; Fasano A;
    Proc Natl Acad Sci U S A; 2021 Jul; 118(29):. PubMed ID: 34253606
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders.
    Aron-Wisnewsky J; Vigliotti C; Witjes J; Le P; Holleboom AG; Verheij J; Nieuwdorp M; Clément K
    Nat Rev Gastroenterol Hepatol; 2020 May; 17(5):279-297. PubMed ID: 32152478
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting the Gut Microbiome to Treat Metabolic Dysfunction-Associated Fatty Liver Disease: Ready for Prime Time?
    Lanthier N; Delzenne N
    Cells; 2022 Aug; 11(17):. PubMed ID: 36078124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.